Inhibition of sonic hedgehog and notch pathways enhances sensitivity of cd133+ glioma stem cells to temozolomide therapy

Molecular Medicine

Volumn 17, Issue 1-2, 2011, Pages 103-112

  Ulasov, Ilya V ^a   Nandi, Suvobroto ^a   Dey, Mahua ^a   Sonabend, Adam M ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CYCLOPAMINE; FLICE INHIBITORY PROTEIN; GAMMA SECRETASE INHIBITOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GSI 1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CELL POPULATION; CELL SELECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION;

ANTIGENS, CD; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GLYCOPROTEINS; HEDGEHOG PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 78751640633     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00062     Document Type: Article

References (42)

1. Hegi ME, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352:997-1003.
2. Stupp R, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996.
3. Branch P, Aquilina G, Bignami M, Karran P. (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362:652-654.
4. Dosch J, Christmann M, Kaina B. (1998) Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 19:567-573.
5. Yip S, et al. (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15:4622-4629.
6. Chua C, et al. (2008) Characterization of a side population of astrocytoma cells in response to temozolomide. J. Neurosurg. 109:856-866.
7. Bleau AM, et al. (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226-235.
8. Bao S, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760.
9. Pollard SM, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumorspecific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568-580.
10. Palos TP, Zheng S, Howard BD. (1999) Wnt signaling induces GLT-1 expression in rat C6 glioma cells. J. Neurochem. 73:1012-1023.
11. Sareddy GR, Challa S, Panigrahi M, Babu PP. (2009) Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem. Res. 34:1278-1288.
12. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. (2002) Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21:878-889.
13. Dahmane N, et al. (2001) The Sonic Hedgehog- Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128:5201-5212.
14. Ehtesham M, et al. (2007) Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 26:5752-5761.
15. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17:165-172.
16. Artavanis-Tsakonas S, Rand MD, Lake RJ. (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770-776.
17. Miele L, Osborne B. (1999) Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 181:393-409.
18. Purow BW, et al. (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65:2353-2363.
19. Zhang XP, et al. (2008) Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol. Cell. Biochem. 307:101-108.
20. Lee J, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403.
21. Bao S, et al. (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68:6043-6048.
22. Wang J, et al. (2008) c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 3:e3769.
23. Sodsai P, Hirankarn N, Avihingsanon Y, Palaga T. (2008) Defects in Notch1 upregulation upon activation of T cells from patients with systemic lupus erythematosus are related to lupus disease activity. Lupus 17:645-653.
24. Karlsson C, et al. (2007) Differentiation of human mesenchymal stem cells and articular chondrocytes: analysis of chondrogenic potential and expression pattern of differentiation-related transcription factors. J. Orthop. Res. 25:152-163.
25. Platet N, et al. (2007) Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258:286-290.
26. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8:131-137.
27. Meloni AR, et al. (2006) Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol. Cell. Biol. 26:7550-7560.
28. Chou TC. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440-446.
29. Joo KM, Nam DH. (2009) Prospective identification of cancer stem cells with the surface antigen CD133. Methods Mol. Biol. 568:57-71.
30. Wu A, et al. (2008) Persistence of CD133 cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 17:173-184.
31. Murat A, et al. (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26:3015-3024.
32. Liu G, et al. (2006) Analysis of gene expression and chemoresistance of CD133 cancer stem cells in glioblastoma. Mol. Cancer 5:67.
33. Chen JK, Taipale J, Cooper MK, Beachy PA. (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16:2743-2748.
34. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. (2002) Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. U. S. A. 99:14071-14076.
35. Taipale J, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406:1005-1009.
36. Fan X, et al. (2010) Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28:5-16.
37. Tammam J, et al. (2009) Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br. J. Pharmacol. 158:1183-1195.
38. Chou TC, Talalay P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
39. Weng AP, et al. (2003) Growth suppression of pre- T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23:655-664.
40. Bar EE, et al. (2007) Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25:2524-2533.
41. Kanamori M, et al. (2007) Contribution of Notch signaling activation to human glioblastoma multiforme. J. Neurosurg. 106:417-427.
42. Shih AH, Holland EC. (2006) Notch signaling enhances nestin expression in gliomas. Neoplasia 8:1072-1082.